BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5789389A · kind A · utility
29Cited by
2References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 17, 1995 |
| Grant date | Aug 4, 1998 |
| Priority date | — |
| Expiry date | Mar 17, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides genetic suppressor elements that are derived from the apoptosis-related gene BCL2. The invention provides genetic suppressor elements that are capable of inhibiting BCL2 gene expression and BCL2-mediated suppression of apoptosis in mammalian cells. The GSEs provided by the invention are also useful for sensitizing cancer cells to the cytotoxic effects of chemotherapeutic drugs. The invention provides methods for identifying and obtaining such elements, and therapeutic methods of using such elements for treatment of cancer cells and animals bearing malignant tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.